1.\tA.S. Jaffe, L. Babuin e F.S. Apple, Biomarkers in acute cardiac disease: the present and the future in J. Am. Coll. Cardiol., vol. 48, n\u00ba 1, luglio 2006
\n2.\tAmerican Heart Association: WARNING SIGNS OF HEART ATTACK, STROKE & CARDIAC ARREST
\n3.\tAssociazioni dei cardiopatici, Il RITARDO EVITABILE: 15 anni dopo
\n4.\tBertram G. Katzung, Farmacologia generale e clinica, Padova, Piccin, 2006, p. 188, ISBN 88-299-1804-0.
\n5.\tBrunton, Lazo, Parker, Goodman & Gilman – Le basi farmacologiche della terapia 11\/ed, McGraw Hill, 2006, ISBN 978-88-386-3911-1.
\n6.\tC. Donfrancesco, L. Palmieri; MT. Cooney; D. Vanuzzo; S. Panico; G. Cesana; M. Ferrario; L. Pilotto; IM. Graham; S. Giampaoli, Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts? in Eur J Cardiovasc Prev Rehabil, vol. 17, n\u00ba 4, agosto 2010, pp. 403-9, DOI:10.1097\/HJR.0b013e328334ea70, PMID 20351552
\n7.\tD. Fontana et al., IL RITARDO EVITABILE NEL PAZIENTE CON INFARTO MIOCARDICO ACUTO:I RISULTATI. (PDF), 2010.
\n8.\tDaniele Bracchetti, Guadagna RF, Calmieri M, Le aritmie cardiache clinica, terapia medica e invasiva terza edizione pagina 221, Padova, Piccin, 1999, ISBN 88-299-1378-2.
\n9.\tESC Guidelines in Myocardial Revascularisation. European Heart Journal (2014); 35(37):2541-619 – doi:10.1093\/eurheartj\/ehu278
\n10.\tEttore Bartoli, Medicina Interna: Metodologia, Semeiotica, Fisiopatologia, Clinica, Terapia Medica, Genova, Restless Architect of Human Possibilities sas (R.A.H.P.sas), 2010
\n11.\tEur Heart J, vol. 32, n\u00ba 1, gennaio 2011, pp. 75-83, DOI:10.1093\/eurheartj\/ehq370, PMID 20971747 12.\tEuropean guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701. 13.\tFaisal A. Arain, et al. Sex\/Gender Medicine The Biological Basis for Personalized Care in Cardiovascular Med Circ J 2009 October; 73(10): 1774-1782.
\n14.\tFederazione Italiana di Cardiologia – www.federcardio.it
\n15.\tFondazione Italiana Cuore e Circolazione – www.fondazioneitalianacuorecircolazione.it
\n16.\tGrundy SM, Brewer HB Jr, Cleeman JL, Smith SC Jr, Lenfrant C. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/ American Heart Association conference on scientific issues related to definition . 2004, 109, 433-438
\n17.\tGruppo di Ricerca del Progetto Registro per gli Eventi Coronarici e Cerebrovascolari. Registro nazionale italiano degli eventi coronarici maggiori: tassi di attacco e letalit\u00e0 nelle diverse aree del paese. Ital Heart J 2005
\n18.\tH.G. Mather et al., Acute myocardial infarction: home and hospital treatment in Br Med J, vol. 3, n\u00ba 5770, agosto 1971, pp. 334\u2013338, PMC 1798627, PMID 5558187 20.\tH.M. Lakka, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men in JAMA, vol. 288, 2002, p. 2709.
\n19.\tHarvard Medical School website – www.health.harvard.edu
\n20.\tI. Adler, I. M. Stratton, H. A. Neil; et al, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study in BMJ, vol. 321, 2000, pp. 412-419
\n21.\tIl Cuore delle Donne, Gruppo di Lavoro della Societ\u00e0 Italiana di Cardiologia 2007
\n22.\tIstituto Superiore di Sanit\u00e0 \u2013 Progetto Cuore – www.cuore.iss.it
\n23.\tK Thygesen e J.S. Alpert, Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction in Eur. Heart J., vol. 21, n\u00ba 18, settembre 2000, pp. 1502\u201313, DOI:10.1053\/euhj.2000.2305, PMID 10973764
\n24.\tK Thygesen, J.S. Alpert e H.D. White, Universal definition of myocardial infarction in Eur. Heart J., vol. 28, n\u00ba 20, ottobre 2007
\n25.\tL. Raffo et al., IL RITARDO EVITABILE NELL’INFARTO MIOCARDICO ACUTO: L\u2019INFORMAZIONE AI CITTADINI (PDF), 2010.
\n26.\tLeuzzi C, Sangiorgi GM, Modena MG. Gender-specific aspects in the clinical presentation of cardiovascular disease. Fundam Clin Pharmacol 2010 Sep 14. doi: 10.1111\/j.1472-8206.2010.00873.x.
\n27.\tM. Sclavo, Cardiovascular risk factors and prevention in women: similarities and differences in Ital Heart J Suppl, vol. 2, n\u00ba 2, febbraio 2001
\n28.\tMinistero della Salute \u2013 Linee Guida per la prevenzione dell\u2019aterosclerosi, 2004
\n29.\tMinistero della Salute \u2013 Relazione sullo stato sanitario del Paese \u2013 www.rssp.salute.gov.it
\n30.\tModena MG, Volpe M. Prevenzione dell\u2019infarto miocardico nella donna. Documento del Gruppo di lavoro SIPREC 2009.
\n31.\tNational Heart, Lung and Blood Institute \u2013 U.S. Department of Health & Human Services
\n32.\tO. Nyg\u00e5rd, SE. Vollset; H. Refsum; I. Stensvold; A. Tverdal; JE. Nordrehaug; M. Ueland; G. Kv\u00e5le, Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. in JAMA, vol. 274, n\u00ba 19, Nov 1995, pp. 1526-33, PMID 7474221
\n33.\tOsservatorio Epidemiologico Cardiovascolare Italiano. Ital Heart J 2004
\n34.\tPatrizia Presbitero, Il cuore della donna, Milano, One Global Medicine, 2014
\n35.\tPsaty BM, Smith NS, Siscovick DS, Esisti clinici associati alle terapie antipertensive utilizzate come prima scelta. Rassegna sistematica e meta-analisi. in Jama (edizione italiana), vol. 9, 1997, pp. 292-302.
\n36.\tRB. D’Agostino, RS. Vasan; MJ. Pencina; PA. Wolf; M. Cobain; JM. Massaro; WB. Kannel, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. in Circulation, vol. 117, n\u00ba 6, febbraio 2008, pp. 743-53, DOI:10.1161\/CIRCULATIONAHA.107.699579, PMID 18212285
\n37.\tRM. Conroy, K. Py\u00f6r\u00e4l\u00e4; AP. Fitzgerald; S. Sans; A. Menotti; G. De Backer; D. De Bacquer; P. Ducimeti\u00e8re; P. Jousilahti; U. Keil; I. Nj\u00f8lstad, Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. in Eur Heart J, vol. 24, n\u00ba 11, giugno 2003, pp. 987-1003, PMID 12788299.
\n38.\tS Mendis et al., World Health Organization definition of myocardial infarction: 2008-09 revision in Int J Epidemiol, vol. 40, n\u00ba 1, febbraio 2011
\n39.\tSara Princivalle, Strategie ed interventi per la prevenzione delle malattie cardiovascolari, 2013.
\n40.\tSociet\u00e0 Italiana di Cardiologia – www.sicardiologia.it\/Sito
\n41.\tWork Package 6 – WP6 Progetto EuroHeart. European Heart Network e Societ\u00e0 Europea di Cardiologia
\n42.\tWorld Health Organization: Joint WHO\/FAO expert consultation on diet, nutrition and the prevention of chronic diseases, Report No. 916, 2002.
\n43.\tWorld Health Report 2002: Reducing risks, promoting healty life, Ginevra, 2002
\n44.\tWorld Heart Federation 2013
\n45.\tY. Harano, M. Suzuki, Y. Koyama, et al, Multifactorial insulinresistance and clinical impact in hypertension and cardiovascular diseases in J Diabetes Complications, vol. 16, 2002, pp. 19-23.<\/p>\n","protected":false},"excerpt":{"rendered":"
1. A.S. Jaffe, L. Babuin e F.S. Apple, Biomarkers in acute cardiac disease: the present and the future in J. Am. Coll. Cardiol., vol. 48, n\u00ba 1, luglio 2006 2. American Heart Association: WARNING SIGNS OF HEART ATTACK, STROKE & CARDIAC ARREST 3. Associazioni dei cardiopatici, Il RITARDO EVITABILE: 15 anni dopo 4. Bertram G.<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/pages\/94"}],"collection":[{"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/comments?post=94"}],"version-history":[{"count":5,"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/pages\/94\/revisions"}],"predecessor-version":[{"id":3039,"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/pages\/94\/revisions\/3039"}],"wp:attachment":[{"href":"https:\/\/test.cristianomichelangeli.com\/vivi2019\/wp-json\/wp\/v2\/media?parent=94"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}